CG
PBYI icon

Caprock Group’s Puma Biotechnology PBYI Stock Holding History

Caprock Group’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Sell
13,862
-12,127
-47% -$88.8K ﹤0.01% 1201
2026
Q1 		$166K Buy
25,989
+9,541
+58% +$61.5K ﹤0.01% 1062
2025
Q4 		$97.9K Buy
16,448
+4,680
+40% +$24.9K ﹤0.01% 1159
2025
Q3 		$59.3K Buy
+11,768
New +$49.9K ﹤0.01% 1106
2025
Q1 		$40.9K Buy
+13,817
New +$43.3K ﹤0.01% 1057

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caprock Group's PBYI Position: Q2 2026 in Review

Caprock Group reduced its Puma Biotechnology (PBYI) stake by 47% in Q2 2026, selling an estimated $88.8K and leaving 13,862 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

Caprock Group first reported a position in PBYI in Q1 2025 and has held it in 5 quarters since. The position peaked at $166K in Q1 2026. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Caprock Group held 13,862 shares of Puma Biotechnology worth $112K as of Q2 2026.
  • Caprock Group sold 12,127 Puma Biotechnology shares in Q2 2026, an estimated $88.8K.
  • Puma Biotechnology made up ﹤0.01% of Caprock Group's portfolio in Q2 2026, its #1201 holding.
  • Caprock Group first reported a position in Puma Biotechnology in Q1 2025 and has held it in 5 quarters since.
  • Caprock Group's Puma Biotechnology position peaked at $166K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.